ENSC
ENSC
NASDAQ · Biotechnology

Ensysce Biosciences Inc

$0.41
+0.01 (+3.05%)
Financial Highlights (FY 2026)
Revenue
38.53M
Net Income
-77,381,167
Gross Margin
—
Profit Margin
-200.8%
Rev Growth
+26.2%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 48.7% 48.7%
Operating Margin -202.1% -181.9% -7.6% -7.6%
Profit Margin -200.8% -190.8% -6.6% -5.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 38.53M 30.53M 257.5K 229.4K
Gross Profit — — 125.5K 111.8K
Operating Income -77,875,158 -55,532,558 -19,525 -17,347
Net Income -77,381,167 -55,180,294 -16,876 -13,616
Gross Margin — — 48.7% 48.7%
Operating Margin -202.1% -181.9% -7.6% -7.6%
Profit Margin -200.8% -190.8% -6.6% -5.9%
Rev Growth +26.2% +26.2% +2.0% +15.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 301.2K 301.2K 414.2K 358.8K
Total Equity 3.72M 3.72M 1.33M 1.24M
D/E Ratio 0.08 0.08 0.31 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -77,826,512 -58,581,084 -21,131 -19,685
Free Cash Flow — — -13,268 -16,406